US2002137142A1PendingUtilityA1
Tango-73 nucleic acids
Est. expiryAug 6, 2017(expired)· nominal 20-yr term from priority
C12N 9/6489C07K 14/70578C07K 14/47C07K 2319/00A61K 38/00A01K 2217/05
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, polypeptides, nucleic acid molecules encoding Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, and uses thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, the cDNA insert of the plasmid deposited with ATCC as Accession Number______, or a complement thereof; b) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, the cDNA insert of the plasmid deposited with ATCC as Accession Number______, or a complement thereof; c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______; d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______; and e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, or a complement thereof under stringent conditions.
2 . The isolated nucleic acid molecule of claim 1 , which is selected from the group consisting of:
a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, the cDNA insert of the plasmid deposited with ATCC as Accession Number______, or a complement thereof; and b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______.
3 . The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.
4 . The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.
5 . A host cell which contains the nucleic acid molecule of claim 1 .
6 . The host cell of claim 5 which is a mammalian host cell.
7 . A non-human mammalian host cell containing the nucleic acid molecule of claim 1 .
8 . An isolated polypeptide selected from the group consisting of:
a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8; b) a naturally occurring allelic variant of a 9 polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, or a complement thereof under stringent conditions; and c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, or a complement thereof.
9 . The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______.
10 . The polypeptide of claim 8 further comprising heterologous amino acid sequences.
11 . An antibody which selectively binds to a polypeptide of claim 8 .
12 . A method for producing a polypeptide selected from the group consisting of:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______; b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______; and c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:10, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, or a complement thereof under stringent conditions; comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.
13 . A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:
a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8 ; and
b) determining whether the compound binds to the polypeptide in the sample.
14 . The method of claim 13 , wherein the compound which binds to the polypeptide is an antibody.
15 . A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.
16 . A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
17 . The method of claim 16 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
18 . A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.
19 . A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:
a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
b) determining whether the polypeptide binds to the test compound.
20 . The method of claim 19 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
a) detection of binding by direct detecting of test compound/polypeptide binding; b) detection of binding using a competition binding assay; c) detection of binding using an assay for Tango-71, Tango-73, Tango-74, Tango-76, or Tango-83-mediated signal transduction.
21 . A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
22 . A method for identifying a compound which modulates the activity of a polypeptide of claim 8 , comprising:
a) contacting a polypeptide of claim 8 with a test compound; and b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.